ANTIANGIOGENIC DRUGS USED FOR THE TREATMENT OF EYE DISEASES
Abstract:
After countless recent studies, the introduction of therapy with anti-VEGF agents in
ophthalmology has been revolutionizing the therapeutic management of exudative and vascular
proliferative diseases. Currently, injections with anti-VEGF agents are part of the first course of
treatment in age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein
occlusion (RVO). Also, they are considered as part of adjunctive therapy in ophthalmic diseases like
proliferative diabetic retinopathy (PDR) and neovascular glaucoma (NVG). Antiangiogenic agents have
been used successfully in the treatment of rare diseases as: sickle cell retinopathy, retinopathy of
prematurity, radiation retinopathy and other vascular diseases proliferative. In any case, the safety and
potential toxicity of this long-term therapy need to be monitored in the future.
full text article in English (.EN) |